Tecfidera (Dimethyl Fumarate) Patent Expiration, LOE Window & CMS Spending

Tecfidera (Dimethyl Fumarate) by Biogen: FDA Orange Book LOE 2035-11-16, 12 AB generics, $189.8M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBiogen
FDA Application & PathwayN204063 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2035-11-16
Orange Book Patents (*PED Extensions)9 patents (0 *PED)
Active AB-Rated Generic Competitors12
2024 CMS Total Public Spend$189.8M
2024 Medicare Part D Spend$162.8M
2024 Medicaid Spend$27.0M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Biogen across sibling Meru public-data platforms.